In clinical studies, cilostazol treatment decreased P2Y12 reactivity index as a marker of platelet function [32], also decreased hsCRP and soluble CD40 ligand levels, and increased adiponectin level in diabetic patients with peripheral arterial occlusion disease [14]. Here, P2RY12 is linked to Peripheral arterial stenosis.